Incorporating the Next Generation of Immunotherapies Into the Treatment of Multiple Myeloma
CAR-T and bispecific antibody therapies now offer multiple options for myeloma patients, with practical guidance expanding their use earlier in treatment.
This JNCCN review from Memorial Sloan Kettering's Myeloma Service comprehensively covers all 6 currently FDA-approved CAR-T and bispecific antibody agents for multiple myeloma, including emerging data for earlier treatment lines and practical guidance on sequencing immunotherapy and managing unique toxicities including CRS, ICANS, cytopenias, and heightened infection risk. The review identifies immunotherapy as now central to MM treatment and poised for broader frontline use.
What the study was
- Study design
- Narrative review
- Population
- Multiple myeloma patients (relapsed/refractory and newly diagnosed)
- Category
- Treatment Innovation
- Maturity
- Validated
- Journal
- Journal of the National Comprehensive Cancer Network
Why it surfaced
Authoritative JNCCN review from MSK Myeloma Service covering full landscape of 6 FDA-approved CAR-T + BsAb agents and frontline development; strong clinical reference for downstream pipeline synthesis
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.